The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Open accessAbstract
BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments. RESULTS: Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects. CONCLUSIONS: The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An example of an early precursor to the SMART is the Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) [54] in chronic schizophrenia.”
From Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research (2014) · cites this paper as [54]
In the citing paper
“In schizophrenia, for example, recent studies have shown that since the introduction of second-generation antipsychotics, treatment efficacy has only marginally improved over traditional dopamine D-2 antagonists, which were introduced 50 years ago (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“While effective in reducing the positive symptoms, the cognitive dysfunctions and negative symptoms, two major determinants for outcome and level of functioning, remained unchanged in the large majority of patients.”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“Over the last 50 years, the pharmacological therapy of schizophrenia was based mainly on the dopamine hypothesis and made little progress (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,056
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,022
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Self-citationLeucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,049
Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
Kane, J. M., & Correll, C. U. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06264yel · Cited by 239
INRICH: interval-based enrichment analysis for genome-wide association studies
Lee, P. H., O'Dushlaine, C., Thomas, B., & Purcell, S. M. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts191 · Cited by 238
Ballard, C. G., Lana, M. M., Theodoulou, M., Douglas, S., McShane, R. H., Jacoby, R. J., Kossakowski, K., Yu, L., Juszczak, E., & on behalf of the Investigators DART AD (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050076 · Cited by 236
Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia
Greene, C., Kealy, J., Humphries, M. M., Gong, Y., Hou, J., Hudson, N., Cassidy, L. M., Martiniano, R., Shashi, V, Hooper, S. R., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.156 · Cited by 235
Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G., & Ellingrod, V. L. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1890 · Cited by 235
de la Fuente‐Sandoval, C., León-Ortíz, P., Favila, R., Stephano, S., Mamo, D. C., Ramírez‐Bermúdez, J., & Graff‐Guerrero, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.65 · Cited by 235
Meyers, B. S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.79 · Cited by 235
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234
Does switching to a new antipsychotic improve outcomes?
Rosenheck, R. A., Thomas, S., Covell, N. H., Essock, S. M., Swartz, M. S., Stroup, T. S., McEvoy, J. P., & Lieberman, J. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.031 · Cited by 233
Self-citationAdd-on Treatment of Benzoate for Schizophrenia
Lane, H., Lin, C., Green, M. F., Hellemann, G., Huang, C., Chen, P., Tun, R., Chang, Y.-C., & Tsai, G. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2159 · Cited by 233
Impact of primary negative symptoms on functional outcomes in schizophrenia
Fervaha, G., Foussias, G., Agid, O., & Remington, G. J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2014.01.007 · Cited by 233
Metabolic syndrome and mental illness.
Newcomer, J. W. (2007) · PubMed · Cited by 232
The Dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions
Sathappan, A. V., Luber, B. M., & Lisanby, S. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.10.006 · Cited by 234
Marder, S. R., Kramer, M. L., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., & Lowy, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.017 · Cited by 228
Fifty years chlorpromazine: a historical perspective
Ban, T. A. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a922 · Cited by 227
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 227
Martin, B. C., Wiley-Exley, E. K., Richards, S., Domino, M. E., Carey, T. S., & Sleath, B. L. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1k671 · Cited by 226
Alonso, J., & Lépine, J. (2007) · PubMed · Cited by 226
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225
Vitiello, B., Correll, C. U., van Zwieten‐Boot, B., Zuddas, A., Parellada, M., & Arango, C. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.008 · Cited by 225
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 225
Self-citationInfluence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224
Riley, B. P., Thiselton, D. L., Maher, B. S., Bigdeli, T., Wormley, B., McMichael, G. O., Fanous, A. H., Vladimirov, V. I., O’Neill, F. A., Walsh, D., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.109 · Cited by 224
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.006 · Cited by 223
Self-citationSibitz, I., Amering, M., Unger, A., Seyringer, M.-E., Bachmann, A. F., Schrank, B., Benesch, T., Schulze, B., & Woppmann, A. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.08.010 · Cited by 222
Sabé, M., Pillinger, T., Kaiser, S., Chen, C., Taipale, H. T., Tanskanen, A. J., Tiihonen, J., Leucht, S., Correll, C. U., & Solmi, M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104608 · Cited by 222
Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia
Yang, J.-W., Bahk, W., Cho, H.-S., Jeon, Y., Jon, D., Jung, H., Kim, C., Kim, H., Kim, Y., Kim, Y. H., et al. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181dcda50 · Cited by 220
Paliperidone Palmitate for Schizophrenia
Nussbaum, A. M., & Stroup, T. S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs099 · Cited by 220
Self-citationKumra, S., Kranzler, H. N., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 219
Neurological complications of psychiatric drugs: clinical features and management
Haddad, P. M., & Dursun, S. M. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.918 · Cited by 219
Persistence and compliance to antidepressant treatment in patients with depression: A chart review
Sawada, N., Uchida, H., Suzuki, T., Watanabe, K., Kikuchi, T., Handa, T., & Kashima, H. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-38 · Cited by 219
Kramer, M. L., Simpson, G. M., Mačiulis, V., Kushner, S. F., Vijapurkar, U., Lim, P., & Eerdekens, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802dda4a · Cited by 219
The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities
Carpenter, W. T., & Koenig, J. I. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301639 · Cited by 218
Meltzer, H. Y. (2012) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.6.3.5 · Cited by 218
Harrow, M., & Jobe, T. H. (2007) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000253783.32338.6e · Cited by 217
Neuropsychiatric Disease and Toxoplasma gondii Infection
Henriquez, S., Brett, R. R., Alexander, J. K., Pratt, J. A., & Roberts, C. W. (2009) · NeuroImmunoModulation · doi:10.1159/000180267 · Cited by 217
Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review
Murphy, B., Chung, Y., Park, T.-W., & McGorry, P. D. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.002 · Cited by 217
Zebrafish models in neuropsychopharmacology and CNS drug discovery
Khan, K. M., Collier, A. D., Мешалкина, Д. А., Kysil, E. V., Khatsko, S. L., Kolesnikova, T. O., Morzherin, Y. Y., Warnick, J. E., Kalueff, A. V., & Echevarria, D. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13754 · Cited by 217
Manoach, D. S., Pan, J. Q., Purcell, S., & Stickgold, R. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.003 · Cited by 216
Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns
Steinberg, M., & Lyketsos, C. G. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12030342 · Cited by 216
Correll, C. U., Rubio, J. M., Inczedy-Farkas, G., Birnbaum, M. L., Kane, J. M., & Leucht, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0624 · Cited by 214
Schizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression
Huang, J., Perlis, R. H., Lee, P. H., Rush, A. J., Fava, M., Sachs, G. S., Lieberman, J., Hamilton, S. P., Sullivan, P., Sklar, P., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091335 · Cited by 213
Self-citationHall‐Flavin, D. K., Winner, J. G., Allen, J. D., Carhart, J. M., Proctor, B. D., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Geske, J. R., & Mrazek, D. A. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283649b9a · Cited by 213
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial
Attia, E., Steinglass, J. E., Walsh, B. T., Wang, Y., Wu, P., Schreyer, C., Wildes, J., Yilmaz, Z., Guarda, A. S., Kaplan, A. S., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18101125 · Cited by 211
The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology
Smeland, O. B., Frei, O., Dale, A. M., & Andreassen, O. A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0364-0 · Cited by 214
Comer, A. L., Carrier, M., Tremblay, M., & Cruz‐Martín, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00274 · Cited by 212
Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W. W., & Uchida, H. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu030 · Cited by 210
Robinson, D. J., Coons, M., Haensel, H., Vallis, M., & Yale, J.-F. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.031 · Cited by 209
Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., Raskind, M. A., & Peskind, E. R. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181ab8c61 · Cited by 209
Hert, M. A. F. D., van Winkel, R., Eyck, D. V., Hanssens, L. S., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-14 · Cited by 209
Harrow, M., Jobe, T. H., & Faull, R. N. (2012) · Psychological Medicine · doi:10.1017/s0033291712000220 · Cited by 208
Amisulpride versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Neto, J. I. S. D. M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006624.pub2 · Cited by 207
Molecular profiles of schizophrenia in the CNS at different stages of illness
Narayan, S., Tang, B., Head, S. R., Gilmartin, T. J., Sutcliffe, J. G., Dean, B., & Thomas, E. A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.023 · Cited by 207
Safety and tolerability of antipsychotic polypharmacy
Gallego, J. A., Nielsen, J., Binder, M. D., Kane, J. M., & Correll, C. U. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.683523 · Cited by 207
Schlosser, D. A., Campellone, T. R., Truong, B., Etter, K., Vergani, S., Komaiko, K., & Vinogradov, S. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby078 · Cited by 206
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
Swanson, J. W., Swartz, M. S., Dorn, R. A. V., Volavka, J., Monahan, J. T., Stroup, T. S., McEvoy, J. P., Wagner, H. R., Elbogen, E. B., & Lieberman, J. A. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042630 · Cited by 206
Self-citationUnexplained Variation Across US Nursing Homes in Antipsychotic Prescribing Rates
Chen, Y. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.469 · Cited by 205
D2Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis
Zhang, J., Lencz, T., & Malhotra, A. K. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09040598 · Cited by 205
Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Mohamed, S., Rosenheck, R. A., Swartz, M. S., Stroup, T. S., Lieberman, J. A., & Keefe, R. S. E. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111713 · Cited by 205
Self-citationThe Future of Psychiatric Research: Genomes and Neural Circuits
Akil, H., Brenner, S., Kandel, E. R., Kendler, K. S., King, M., Scolnick, E. M., Watson, J. D., & Zoghbi, H. Y. (2010) · Science · doi:10.1126/science.1188654 · Cited by 204
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
Peluso, M. J., Lewis, S. W., Barnes, T. R. E., & Jones, P. B. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.101485 · Cited by 204
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 204
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Tandon, R., Nasrallah, H. A., Akbarian, S., Carpenter, W. T., DeLisi, L. E., Gäebel, W., Green, M. F., Gur, R. E., Heckers, S., Kane, J. M., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.015 · Cited by 205
Capasso, R., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & Sauver, J. L. S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.005 · Cited by 202
Kaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
GOFF, D. C., Falkai, P., Fleischhacker, W. W., Girgis, R. R., Kahn, R. S., Uchida, H., Zhao, J., & Lieberman, J. A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091016 · Cited by 201
Self-citationOsborn, D. P. J., Hardoon, S., Omar, R. Z., Holt, R. I. G., King, M., Larsen, J., Marston, L., Morris, R. W., Nazareth, I., Walters, K., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2133 · Cited by 200
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111609 · Cited by 200
Self-citationPathways to Aggression in Schizophrenia Affect Results of Treatment
Volavka, J., & Citrome, L. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr041 · Cited by 200
Cognitive-behavioral therapy for medication-resistant psychosis: A meta-analytic review
Burns, A. M. N., Erickson, D. H., & Brenner, C. A. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300213 · Cited by 199
Sun, S. X., Liu, G. G., Christensen, D. B., & Fu, A. Z. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226050 · Cited by 198
Fleischhacker, W. W., Heikkinen, M. E., Olié, J., Landsberg, W., Dewaele, P., McQuade, R. D., Loze, J.-Y., Hennicken, D., & Kerselaers, W. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000490 · Cited by 199
Unique Effects of Clozapine: A Pharmacological Perspective
Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.009 · Cited by 198
The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115225 · Cited by 197
Deegan, P. E. (2007) · Psychiatric Rehabilitation Journal · doi:10.2975/31.1.2007.62.69 · Cited by 197
Ng, F., Mammen, O. K., Wilting, I., Sachs, G. S., Ferrier, I. N., Cassidy, F., Beaulieu, S., Yatham, L. N., & Berk, M. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00737.x · Cited by 196
Iloperidone, asenapine and lurasidone: a primer on their current status
Tarazi, F. I., & Stahl, S. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.712114 · Cited by 196
Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
Devanand, D. P., Mintzer, J. E., Schultz, S. K., Andrews, H., Sultzer, D. L., de la Pena, D., Gupta, S., Colon, S., Schimming, C., Pelton, G. H., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114058 · Cited by 196
Oral paliperidone for schizophrenia
Nussbaum, A. M., & Stroup, T. S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006369.pub2 · Cited by 195
Self-citationCorrell, C. U., Penzner, J. B., Frederickson, A. M., Richter, J. J., Auther, A. M., Smith, C. W., Kane, J. M., & Cornblatt, B. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm028 · Cited by 195
Why don't patients take their medicine? Reasons and solutions in psychiatry
Mitchell, A. J., & Selmes, T. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.106.003194 · Cited by 195
Quetiapine versus typical antipsychotic medications for schizophrenia
Suttajit, S., Srisurapanont, M., Xia, J., Suttajit, S., Maneeton, B., & Maneeton, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007815.pub2 · Cited by 194
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Zhang, J., & Malhotra, A. K. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.532787 · Cited by 194
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
Emsley, R. A., Rabinowitz, J., & Medori, R. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.013 · Cited by 194
Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., & Laszlovszky, I. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.11.041 · Cited by 194
Weight effects associated with antipsychotics: A comprehensive database analysis
Parsons, B., Allison, D. B., Loebel, A. D., Williams, K., Giller, E. L., Romano, S. J., & SIU, C. O. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.025 · Cited by 193
Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications
Woods, S. W., Morgenstern, H., Saksa, J. R., Walsh, B. C., Sullivan, M. C., Money, R. W., Hawkins, K. A., Gueorguieva, R. V., & Glazer, W. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03890yel · Cited by 192
Katschnig, H. (2010) · World Psychiatry · doi:10.1002/j.2051-5545.2010.tb00257.x · Cited by 191
Detecting and defusing cognitive traps: metacognitive intervention in schizophrenia
Moritz, S., Vitzthum, F., Randjbar, S., Veckenstedt, R., & Woodward, T. S. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833d16a8 · Cited by 190
Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Schulz, S. C. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm109 · Cited by 189
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Caroff, S. N., Hurford, I., Lybrand, J., & Campbell, E. C. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.002 · Cited by 188
Tek, C., Küçükgöncü, S., Gülöksüz, S., Woods, S. W., Srihari, V. H., & Annamalai, A. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12251 · Cited by 187
Using a pharmacogenomic algorithm to guide the treatment of depression
Hall‐Flavin, D. K., Winner, J. G., Allen, J. D., Jordan, J. J., Nesheim, R. S., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Biernacka, J. M., & Mrazek, D. A. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.99 · Cited by 187
Weight gain and antipsychotics: a drug safety review
Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.974549 · Cited by 187
Swerdlow, N. R., BRAFF, D. L., & Geyer, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116661075 · Cited by 186
Review: Mortality in schizophrenia: a measurable clinical endpoint
Bushe, C. J., Taylor, M., & Haukka, J. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382468 · Cited by 185
Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia
Spina, E., & Zoccali, R. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.629 · Cited by 185
MicroRNA dysregulation in psychiatric disease
Miller, B. H., & Wahlestedt, C. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.035 · Cited by 185
Metadata
- Authors
- Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K.
- Affiliations
- New York State Psychiatric Institute (US)
- Duke University (US)
- Yale University (US)
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-22
- Volume
- 353
- Issue
- 12
- Pages
- 1209-1223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159155203
- Cited by
- 5,892
- References
- 32
- Citations by year
- 2026: 95 · 2025: 89 · 2024: 135 · 2023: 129 · 2022: 191 · 2021: 166 · 2020: 338 · 2019: 207 · 2018: 211 · 2017: 220 · 2016: 231 · 2015: 277 · 2014: 325 · 2013: 361 · 2012: 379
- FWCI
- 258.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Case Western Reserve University
- Foundation of Hope for Research and Treatment of Mental Illness
- Otsuka Pharmaceutical
- National Institutes of Health (n01mh90001-21-0-0)
- University of North Carolina at Chapel Hill
- National Institute of Mental Health (N01 MH90001, MH90001)
- Janssen Pharmaceuticals
- School of Medicine, University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, atypical antipsychotics, typical antipsychotics, perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, treatment discontinuation, treatment efficacy, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, chronic schizophrenia, double-blind comparison, long-term treatment
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Chronic Disease, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lipids, Male, Patient Compliance, Perphenazine, Piperazines, Schizophrenia, Thiazoles, Antipsychotic Agents, Weight Gain, Proportional Hazards Models, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
